Blog Post

Blog Post

Early Warning Signs Help Spot Neuromuscular Disease in Children

By Shaila Wunderlich | April 2, 2021
Blog Post

Clinical Trial Alert: Phase 2 Study of Pegcetacoplan in Adults with Sporadic ALS (MERIDIAN)

By MDA Staff | March 31, 2021
Blog Post

Research Study Alert: Observational Study of a Smartphone Application to Track Progression of ALS and Related Motor Neuron Diseases

By MDA Staff | March 23, 2021
Blog Post

Clinical Trial Alert: Phase 1/2 Study of AT845 in Late-Onset Pompe Disease

By MDA Staff | March 16, 2021
Blog Post

Clinical Trial Alert: Observational Study to Identify Biomarkers in Individuals Receiving Radicava for ALS

By MDA Staff | March 10, 2021
Blog Post

Clinical Trial Alert: Phase 3 Study of Zilucoplan in Individuals With Generalized Myasthenia Gravis

By MDA Staff | March 2, 2021
Blog Post

FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45

By Sujatha Gurunathan | February 25, 2021
Blog Post

Clinical Trial Alert: Phase 3 Study of Rozanolixizumab in Individuals With Generalized Myasthenia Gravis

By MDA Staff | February 23, 2021
Blog Post

MDA Welcomes Dr. Don Wood as its New President and CEO

By Nancy Intrator | February 16, 2021
Blog Post

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

By Sujatha Gurunathan | February 4, 2021